Brief: Genmab Reports Q1 Operating Profit Of $180 Million
May 7 (Reuters) - Genmab A/S GMAB.CO: IS MAINTAINING ITS 2026 FINANCIAL GUIDANCE Q1 OPERATING PROFIT $180 MILLION VERSUS IBES ESTIMATE $184.7 MILLION Q1 REVENUE $896 MILLION VERSUS $890.4 MILLION SEEN IN LSEG POLL Q1 OPERATING EXPENSES, EXCLUDING ACQUISITION AND INTEGRATION RELATED CHARGES, WERE $606 MILLION Source text: ID:nGNE6Hgwh6 Further company coverage: GMAB.CO (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Genmab A/S
See all newsBrief: Genmab Says Orbis Investment Management Holds 4.99% Of Genmab Voting Rights As Of June 12
Brief: Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
Brief: Genmab Presents Epcore Fl-1 Data Showing Consistent Efficacy, Safety For Epcoritamab Combination
Brief: Genmab Says Orbis Investment Management Limited Holds 5.08% Of Genmab A/S As Of May 8, 2026
Genmab falls after 'uneventful' Q1, profit miss